phrykt

Prime Medicine, Inc. (PRME): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of PRME were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Prime Medicine

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PRME

186 funds and institutions reported PRME shares worth $396M at the end of Q2 2026, about 59% of the company. The largest holder is Alphabet Inc. with 9.2%.

Funds and institutions (13F) 59%Everyone else 41%

10 largest owners, by share of the company

Alphabet Inc.9.2%
BlackRock, Inc.5.3%
ARK Investment Management LLC4.6%
State Street Corp4.2%
T. Rowe Price Investment Management, Inc.2.9%
Vanguard Capital Management LLC2.5%
Balyasny Asset Management L.P.2.2%
Goldman Sachs Group Inc1.9%
Casdin Capital, LLC1.8%
Woodline Partners LP1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Alphabet Inc.16.56M9.17%$61.1MNo change
BlackRock, Inc.9.60M5.32%$35.4M+13%
ARK Investment Management LLC8.35M4.62%$30.8M+34%
State Street Corp7.58M4.19%$28M+19%
T. Rowe Price Investment Management, Inc.5.24M2.90%$19.3M-4%
Vanguard Capital Management LLC4.52M2.50%$16.7M+1%
Balyasny Asset Management L.P.3.97M2.20%$14.6M-4%
Goldman Sachs Group Inc3.43M1.90%$12.7M+254%
Casdin Capital, LLC3.17M1.75%$11.7MNo change
Woodline Partners LP3.00M1.66%$11.1MNo change
UBS Group AG2.79M1.55%$10.3M-3%
Geode Capital Management, LLC2.71M1.50%$10M-1%
Sumitomo Mitsui Trust Group, Inc.2.41M1.34%$8.9M-18%
Amova Asset Management Americas, Inc.2.41M1.33%$8.9M-18%
Citadel Advisors LLC2.05M1.14%$7.6M+511%
ADAR1 Capital Management, LLC2.00M1.11%$7.4M+1%
FMR LLC (Fidelity)1.76M0.98%$6.5M-0%
Two Sigma Investments, LP1.52M0.84%$5.6M-3%
Redmile Group, LLC1.39M0.77%$5.1M-13%
Farallon Capital Management, L.l.c.1.24M0.69%$4.6MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No PRME insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PRME short interest

High short interest. 16.1% of PRME shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 5%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 29.15M PRME shares were sold short, 16.1% of the shares outstanding, down 11.3% from the report before. At the average daily volume of 6.07M shares, buying them all back would take about 4.8 trading days (days to cover).

Shares short, % of all shares

16.1%May 15Oct 3020.9%

Days to cover

4.8May 15Oct 3015.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202629.15M16.07%-11%6.07M4.8
Oct 15, 202632.87M18.12%+2%5.96M5.5
Sep 30, 202632.12M17.71%No change3.80M8.4
Sep 15, 202632.13M17.72%-13%2.61M12.3
Aug 31, 202636.76M20.27%+5%2.80M13.1
Aug 14, 202635.02M19.31%+0%2.53M13.8
Jul 31, 202635.00M19.30%+4%2.71M12.9
Jul 15, 202633.54M18.57%-3%4.98M6.7
Jun 30, 202634.73M19.23%+7%3.81M9.1
Jun 15, 202632.53M18.01%+6%2.88M11.3
May 29, 202630.82M17.06%+1%2.75M11.2
May 15, 202630.53M16.90%+1%2.60M11.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Prime Medicine company events

Prime Medicine filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementThe Company posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 8, 2026AnnouncementPrime Medicine, Inc. received a final award from the arbitration tribunal in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. regarding the parties' 2019 Collaboration and License Agreement. Filing
  4. Jun 8, 2026VoteReported shareholder vote results. Filing
  5. May 7, 2026ResultsReleased financial results. Filing
  6. Apr 16, 2026LeadershipThe Board of Directors of Prime Medicine, Inc. appointed Svetlana Makhni as the Chief Financial Officer and the principal financial officer of the Company effective as of April 16, 2026. Filing
  7. Mar 3, 2026ResultsReleased financial results. Filing
  8. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Prime Medicine financials

Famous investors that hold PRME

5 of the 50 well-known investors we track reported holding PRME in their latest 13F filing. The largest position is Cathie Wood's, worth $30.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 202610.04M$30.7M0.2%+20%
Israel Englander · Millennium ManagementQ3 20261.06M$3.2M0.0%+148%
Steve Cohen · Point72 Asset ManagementQ3 2026753,741$2.3M0.0%+41%
Ken Griffin · Citadel AdvisorsQ3 2026461,974$1.4M0.0%-78%
Paul Tudor Jones · Tudor Investment CorpQ3 202661,542$188K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PRME in the last 120 days.

FiledHolderFormStake
Nov 13, 2026ARCH Venture Fund X, L.P.13D/A8.3%
Nov 13, 2026ARCH Venture Fund X, L.P.13D/A8.3%
Nov 13, 2026ARK Investment Management LLC13G5.5%
Nov 13, 2026ARK Investment Management LLC13G5.5%

Questions about Prime Medicine, Inc. (PRME) stock

Who owns the most PRME stock?

The largest reported owner of Prime Medicine, Inc. (PRME) is Alphabet Inc., with 9.2% of the company. In total, 186 funds and institutions reported holding PRME at the end of Q2 2026, together about 59% of the shares. See the largest owners.

Are PRME insiders buying or selling?

No PRME insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in PRME?

As of Oct 30, 2026, 29.15M PRME shares were sold short, 16.1% of the shares outstanding, down 11.3% from the report before. At the average daily volume of 6.07M shares, buying them all back would take about 4.8 trading days (days to cover). See the history.

Which famous investors hold PRME?

5 of the 50 well-known investors we track reported PRME in their latest 13F filing, including Cathie Wood, Israel Englander, Steve Cohen. The largest position is worth $30.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.